Should I buy or sell Corcept Therapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CORT shares. View CORT analyst ratings or view top-rated stocks .

What is Corcept Therapeutics' stock price target for 2024?

7 analysts have issued twelve-month price targets for Corcept Therapeutics' stock. Their CORT share price targets range from $22.00 to $47.50. On average, they expect the company's stock price to reach $32.19 in the next year. This suggests a possible upside of 26.5% from the stock's current price. View analysts price targets for CORT or view top-rated stocks among Wall Street analysts .

How have CORT shares performed in 2023?

Corcept Therapeutics' stock was trading at $20.31 on January 1st, 2023. Since then, CORT shares have increased by 25.3% and is now trading at $25.45. View the best growth stocks for 2023 here .

Are investors shorting Corcept Therapeutics?

Corcept Therapeutics saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 15,270,000 shares, an increase of 8.1% from the October 31st total of 14,120,000 shares. Based on an average daily volume of 739,700 shares, the short-interest ratio is presently 20.6 days. Approximately 17.4% of the shares of the stock are short sold. View Corcept Therapeutics' Short Interest .

When is Corcept Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our CORT earnings forecast .

How were Corcept Therapeutics' earnings last quarter?

Corcept Therapeutics Incorporated (NASDAQ:CORT) posted its quarterly earnings results on Wednesday, November, 1st. The biotechnology company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.22 by $0.06. The biotechnology company had revenue of $123.60 million for the quarter, compared to the consensus estimate of $119.71 million. Corcept Therapeutics had a net margin of 20.20% and a trailing twelve-month return on equity of 18.99%. The firm's quarterly revenue was up 21.5% compared to the same quarter last year. During the same period last year, the business earned $0.30 earnings per share.

What ETFs hold Corcept Therapeutics' stock?

ETFs with the largest weight of Corcept Therapeutics (NASDAQ:CORT) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP) , Invesco S&P SmallCap Health Care ETF (PSCH) , ALPS Medical Breakthroughs ETF (SBIO) , SPDR S&P Pharmaceuticals ETF (XPH) , Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) , iShares U.S. Pharmaceuticals ETF (IHE) , Hartford Multifactor Small Cap ETF (ROSC) and Distillate Small/Mid Cash Flow ETF (DSMC) .

What is Joseph K. Belanoff's approval rating as Corcept Therapeutics' CEO?

6 employees have rated Corcept Therapeutics Chief Executive Officer Joseph K. Belanoff on Glassdoor.com . Joseph K. Belanoff has an approval rating of 100% among the company's employees. This puts Joseph K. Belanoff in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Corcept Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU) , NVIDIA (NVDA) , Advanced Micro Devices (AMD) , AbbVie (ABBV) , CA (CA) , Alibaba Group (BABA) , BlackRock (BLK) , Inovio Pharmaceuticals (INO) , Pfizer (PFE) and Activision Blizzard (ATVI) .

Who are Corcept Therapeutics' major shareholders?

Corcept Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Ingalls & Snyder LLC (8.13%), Boston Trust Walden Corp (1.78%), Federated Hermes Inc. (1.64%), Northern Trust Corp (1.24%), Morgan Stanley (1.19%) and Invesco Ltd. (0.92%). Insiders that own company stock include Daniel N Swisher Jr , Daniel N Swisher, Jr, David L Mahoney , G Leonard Baker Jr, G Leonard Baker, Jr , Gary Charles Robb , Hazel Hunt , Joseph Douglas Lyon , Joseph K Belanoff and Sean Maduck . View institutional ownership trends .

How do I buy shares of Corcept Therapeutics?

Shares of CORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Corcept Therapeutics Stock Price, News & Analysis (NASDAQ:CORT)

$25.45

+0.18 (+0.71%)

(As of 11/28/2023 ET)

Compare

Today's Range: $24.88
▼
$25.48
50-Day Range: $24.82
▼
$32.99
52-Week Range: $17.86
▼
$34.28

Volume: 406,538 shs
Average Volume: 726,653 shs
Market Capitalization: $2.62 billion

P/E Ratio: 31.42
Dividend Yield: N/A
Price Target: $32.19

Corcept Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.57 Rating Score
Upside/Downside: 26.5% Upside
$32.19 Price Target
Short Interest: Bearish
17.39% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.59
Upright™ Environmental Score
News Sentiment: 1.87
Based on 2 Articles This Week
Insider Trading: Selling Shares
$2.29 M Sold Last Quarter
Proj. Earnings Growth: -10.99%
From $0.91 to $0.81 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.34 out of 5 stars

Medical Sector

268th out of 949 stocks

Pharmaceutical Preparations Industry

113th out of 434 stocks

3.3

Analyst's Opinion

Consensus Rating
Corcept Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $32.19, Corcept Therapeutics has a forecasted upside of 26.5% from its current price of $25.45.
Amount of Analyst Coverage
Corcept Therapeutics has only been the subject of 2 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
17.39% of the float of Corcept Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Corcept Therapeutics has a short interest ratio ("days to cover") of 20.6, which indicates bearish sentiment.
Change versus previous month
Short interest in Corcept Therapeutics has recently increased by 8.14%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Corcept Therapeutics does not currently pay a dividend.
Dividend Growth
Corcept Therapeutics does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Corcept Therapeutics has received a 68.41% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Preclinical research services for physical health", "Clinical research services for cancer", and "Clinical research services for metabolic diseases" products. See details.
Environmental Sustainability
The Environmental Impact score for Corcept Therapeutics is -0.59.

3.3

News and Social Media Coverage

News Sentiment
Corcept Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Corcept Therapeutics this week, compared to 3 articles on an average week.
Search Interest
Only 5 people have searched for CORT on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.
MarketBeat Follows
6 people have added Corcept Therapeutics to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Corcept Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,293,864.00 in company stock.
Percentage Held by Insiders
18.60% of the stock of Corcept Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
78.80% of the stock of Corcept Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Corcept Therapeutics are expected to decrease by -10.99% in the coming year, from $0.91 to $0.81 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Corcept Therapeutics is 31.42, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 121.85.
Price to Earnings Ratio vs. Sector
The P/E ratio of Corcept Therapeutics is 31.42, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 130.61.
Price to Book Value per Share Ratio
Corcept Therapeutics has a P/B Ratio of 5.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Corcept Therapeutics Stock (NASDAQ:CORT)

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. It is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

CORT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CORT Stock News Headlines

November 15, 2023 | morningstar.com

Corcept Therapeutics Inc CORT

November 14, 2023 | finance.yahoo.com

Should Weakness in Corcept Therapeutics Incorporated's (NASDAQ:CORT) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

November 28, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 13, 2023 | seekingalpha.com

Analyzing Corcept's Strategic Shift In A Competitive Pharma Landscape

November 10, 2023 | stocknews.com

Vertex Pharmaceuticals (VRTX) Post-Earnings Analysis: Is It Time to Buy the Stock?

November 7, 2023 | msn.com

Truist Securities Upgrades Corcept Therapeutics (CORT)

November 6, 2023 | msn.com

Truist upgrades Corcept to buy, cites market potential for relacorilant

November 6, 2023 | markets.businessinsider.com

Where Corcept Therapeutics Stands With Analysts

November 28, 2023 | RYSE INC. (Ad)

Secure your stake in the Smart Home industry.

Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.

November 4, 2023 | finance.yahoo.com

Insider Sell: Chief Accounting Officer Joseph Lyon Sells 5,000 Shares of Corcept Therapeutics Inc

November 2, 2023 | finance.yahoo.com

Corcept Therapeutics Incorporated (NASDAQ:CORT) Q3 2023 Earnings Call Transcript

November 2, 2023 | finance.yahoo.com

Corcept (CORT) Beats on Q3 Earnings, Raises '23 Sales View

November 1, 2023 | finance.yahoo.com

Corcept Therapeutics Inc (CORT) Reports 22% Revenue Increase in Q3 2023

November 1, 2023 | finance.yahoo.com

Corcept Appoints Monica Tellado as President, Emerging Markets

October 31, 2023 | finance.yahoo.com

Why Earnings Season Could Be Great for Corcept Therapeutics (CORT)

October 26, 2023 | finance.yahoo.com

Corcept Therapeutics (CORT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

October 12, 2023 | finance.yahoo.com

Tempest (TPST) Up as First-Line Liver Cancer Study Meets Goals

October 5, 2023 | finance.yahoo.com

Pulling back 20% this week, Corcept Therapeutics' NASDAQ:CORT) five-year decline in earnings may be coming into investors focus

October 4, 2023 | finance.yahoo.com

Kezar (KZR) Falls 10% on Strategic Update, Reduces Workforce

October 3, 2023 | msn.com

Truist Securities Reiterates Corcept Therapeutics (CORT) Hold Recommendation

October 2, 2023 | markets.businessinsider.com

5 Analysts Have This to Say About Corcept Therapeutics

September 30, 2023 | msn.com

Corcept Therapeutics plunges amid patent trial with Teva (update)

September 29, 2023 | seekingalpha.com

Corcept Therapeutics plunges amid patent trial with Teva

September 29, 2023 | finance.yahoo.com

MediWound (MDWD) Surges 18.2%: Is This an Indication of Further Gains?

September 28, 2023 | finance.yahoo.com

Viatris (VTRS) Gets FDA Nod for Pupil Dilation Reversal Agent

September 26, 2023 | finance.yahoo.com

Novo Nordisk (NVO), Valo Ink Deal to Develop Heart Disease Drugs

September 25, 2023 | stocknews.com

Investors Keeping a Close Eye on These 3 Biotech Stocks

See More Headlines

Receive CORT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corcept Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/01/2023
Today: 11/28/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/27/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Sector: Medical
Current Symbol: NASDAQ:CORT
CUSIP: 21835210
CIK: 1088856
Web: www.corcept.com
Phone: (650) 327-3270
Fax: 650-327-3218
Employees: 299
Year Founded: 1998

Price Target and Rating

Average Stock Price Target: $32.19
High Stock Price Target: $47.50
Low Stock Price Target: $22.00
Potential Upside/Downside: +28.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.57
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.81
Trailing P/E Ratio: 30.96
Forward P/E Ratio: 27.56
P/E Growth: N/A
Net Income: $101.42 million
Net Margins: 20.20%
Pretax Margin: 24.89%
Return on Equity: 18.99%
Return on Assets: 15.67%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.54
Quick Ratio: 3.48

Sales & Book Value

Annual Sales: $401.86 million
Price / Sales: 6.43
Cash Flow: $0.96 per share
Price / Cash Flow: 26.15
Book Value: $4.66 per share
Price / Book: 5.38

Miscellaneous

Outstanding Shares: 103,080,000
Free Float: 83,908,000
Market Cap: $2.59 billion
Optionable: Optionable
Beta: 0.43

Social Links

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Dr. Joseph K. Belanoff M.D. (Age 66)
Co-Founder, President, CEO & Director
Comp: $1.82M
Mr. Atabak Mokari (Age 46)
CFO & Treasurer
Comp: $760.75k
Dr. Hazel Hunt Ph.D. (Age 63)
Chief Scientific Officer
Comp: $895.16k
Mr. Sean Maduck (Age 46)
President of Corcept Endocrinology
Comp: $823.42k
Mr. Gary Charles Robb (Age 60)
Chief Business Officer & Secretary
Comp: $963k
Mr. Joseph Douglas Lyon (Age 44)
Chief Accounting Officer
Ms. Amy Flood
Chief Human Resources & Communications Officer
Dr. William Guyer Pharm.D. (Age 55)
Chief Development Officer
Ms. Monica Tellado (Age 50)
President of Emerging Markets

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CORT Stock Analysis - Frequently Asked Questions

Should I buy or sell Corcept Therapeutics stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CORT shares.
View CORT analyst ratings or view top-rated stocks.
What is Corcept Therapeutics' stock price target for 2024?: 7 analysts have issued twelve-month price targets for Corcept Therapeutics' stock. Their CORT share price targets range from $22.00 to $47.50. On average, they expect the company's stock price to reach $32.19 in the next year. This suggests a possible upside of 26.5% from the stock's current price.
View analysts price targets for CORT or view top-rated stocks among Wall Street analysts.
How have CORT shares performed in 2023?: Corcept Therapeutics' stock was trading at $20.31 on January 1st, 2023. Since then, CORT shares have increased by 25.3% and is now trading at $25.45.
View the best growth stocks for 2023 here.
Are investors shorting Corcept Therapeutics?: Corcept Therapeutics saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 15,270,000 shares, an increase of 8.1% from the October 31st total of 14,120,000 shares. Based on an average daily volume of 739,700 shares, the short-interest ratio is presently 20.6 days. Approximately 17.4% of the shares of the stock are short sold.
View Corcept Therapeutics' Short Interest.
When is Corcept Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our CORT earnings forecast.
How were Corcept Therapeutics' earnings last quarter?: Corcept Therapeutics Incorporated (NASDAQ:CORT) posted its quarterly earnings results on Wednesday, November, 1st. The biotechnology company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.22 by $0.06. The biotechnology company had revenue of $123.60 million for the quarter, compared to the consensus estimate of $119.71 million. Corcept Therapeutics had a net margin of 20.20% and a trailing twelve-month return on equity of 18.99%. The firm's quarterly revenue was up 21.5% compared to the same quarter last year. During the same period last year, the business earned $0.30 earnings per share.

What ETFs hold Corcept Therapeutics' stock?: ETFs with the largest weight of Corcept Therapeutics (NASDAQ:CORT) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), Invesco S&P SmallCap Health Care ETF (PSCH), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), iShares U.S. Pharmaceuticals ETF (IHE), Hartford Multifactor Small Cap ETF (ROSC) and Distillate Small/Mid Cash Flow ETF (DSMC).
What is Joseph K. Belanoff's approval rating as Corcept Therapeutics' CEO?: 6 employees have rated Corcept Therapeutics Chief Executive Officer Joseph K. Belanoff on Glassdoor.com. Joseph K. Belanoff has an approval rating of 100% among the company's employees. This puts Joseph K. Belanoff in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Corcept Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), CA (CA), Alibaba Group (BABA), BlackRock (BLK), Inovio Pharmaceuticals (INO), Pfizer (PFE) and Activision Blizzard (ATVI).
Who are Corcept Therapeutics' major shareholders?: Corcept Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Ingalls & Snyder LLC (8.13%), Boston Trust Walden Corp (1.78%), Federated Hermes Inc. (1.64%), Northern Trust Corp (1.24%), Morgan Stanley (1.19%) and Invesco Ltd. (0.92%). Insiders that own company stock include Daniel N Swisher Jr, Daniel N Swisher, Jr, David L Mahoney, G Leonard Baker Jr, G Leonard Baker, Jr, Gary Charles Robb, Hazel Hunt, Joseph Douglas Lyon, Joseph K Belanoff and Sean Maduck.
View institutional ownership trends.
How do I buy shares of Corcept Therapeutics?: Shares of CORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CORT) was last updated on 11/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial